NASDAQ:KZIA Novogen (KZIA) Stock Price, News & Analysis $5.49 +0.18 (+3.39%) Closing price 04:00 PM EasternExtended Trading$5.47 -0.02 (-0.36%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainSEC Filings About Novogen Stock (NASDAQ:KZIA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novogen alerts:Sign Up Key Stats Today's Range$5.25▼$5.7550-Day Range$5.31▼$11.8852-Week Range$4.86▼$17.40Volume229,814 shsAverage Volume234,949 shsMarket Capitalization$71.21 millionP/E RatioN/ADividend YieldN/APrice Target$29.50Consensus RatingModerate Buy Company Overview Novogen Limited, now known as Kazia Therapeutics, is an Australian biotechnology company focused on developing therapies for cancer. The company has historically advanced drug candidates aimed at treating tumors with limited treatment options, rather than marketing approved medicines. Its pipeline has included paxalisib, an investigational drug designed to inhibit the PI3K and mTOR pathways and studied for brain cancers, including glioblastoma. Kazia has also developed other experimental oncology candidates, including cantrixil for ovarian cancer. The company traces its roots to Novogen, which adopted the Kazia Therapeutics name in 2016. Based in Australia, it has pursued clinical development programs and collaborations that extend beyond its home market. Its programs remain investigational, and availability or development status may change as clinical research progresses.AI Generated. May Contain Errors. Read More Novogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreKZIA MarketRank™: 3.467601870405 of 5 starsNovogen scored higher than 69% of companies evaluated by MarketBeat, and ranked 269th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNovogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNovogen has a consensus price target of $29.50, representing about 437.3% upside from its current price of $5.49.Amount of Analyst CoverageNovogen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novogen's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.26% of the float of Novogen has been sold short.Short Interest Ratio / Days to CoverNovogen has a short interest ratio ("days to cover") of 7.92.Change versus previous monthShort interest in Novogen has recently increased by 10.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovogen does not currently pay a dividend.Dividend GrowthNovogen does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment-0.27 News SentimentNovogen has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Novogen this week, compared to 1 article on an average week.Search Interest4 people have searched for KZIA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Novogen to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novogen insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of Novogen is held by insiders.Percentage Held by Institutions30.89% of the stock of Novogen is held by institutions.Read more about Novogen's insider trading history. Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KZIA Stock News HeadlinesNovogen Limited (NASDAQ:KZIA) Stock Has Consensus Price Target of $29.50November 13, 2026 | americanbankingnews.comKazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein DegraderNovember 12, 2026 | prnewswire.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 18 at 1:00 AM | Behind the Markets (Ad)Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough AwardsNovember 5, 2026 | prnewswire.comKazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer SymposiumNovember 2, 2026 | prnewswire.comKazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation ConferenceOctober 29, 2026 | prnewswire.comKazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersSeptember 22, 2026 | prnewswire.comKazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain CancerSeptember 9, 2026 | prnewswire.comSee More Headlines KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed this year? Novogen's stock was trading at $6.89 on January 1st, 2026. Since then, KZIA stock has decreased by 20.3% and is now trading at $5.49. When did Novogen's stock split? Novogen shares reverse split on the morning of Monday, October 28th 2024.The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Novogen? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novogen investors own include Ideanomics (IDEX), NIO (NIO), Bionano Genomics (BNGO), Mereo BioPharma Group (MREO), NVIDIA (NVDA), Palantir Technologies (PLTR) and Tesla (TSLA). Company Calendar Today11/18/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 2 days ago, KZIA's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KZIA Previous SymbolASX:KZA CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees6Year Founded1994Price Target and Rating Average Price Target for Novogen$29.50 High Price Target$40.00 Low Price Target$18.00 Potential Upside/Downside+437.3%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.23 million Price / Sales57.89 Cash FlowN/A Price / Cash FlowN/A Book Value($5.34) per share Price / Book-1.03Miscellaneous Outstanding Shares12,970,000Free Float12,839,000Market Cap$71.21 million OptionableOptionable Beta2.34 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:KZIA) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.